載入中
NASDAQHealthcareBiotechnology
最新資料
US$0.5851
−US$0.0138 · -2.30%
Outlook Therapeutics, Inc. is a biopharmaceutical company in the advanced stages of clinical development, focused on inventing and bringing to market monoclonal antibody treatments for various eye conditions. Its flagship drug candidate, ONS-5010, is an ophthalmic formulation of bevacizumab currently undergoing crucial Phase III clinical trials. This investigational product is being evaluated for its potential to treat wet age-related macular degeneration and other serious retinal diseases. The company has forged strategic collaboration and licensing agreements with several partners, including IPCA Laboratories Limited, Laboratorios Liomont, S.A. de C.V., BioLexis Pte. Ltd., and Zhejiang Huahai Pharmaceutical Co., Ltd. Incorporated in 2010, the firm was formerly known as Oncobiologics, Inc., changing its name to Outlook Therapeutics, Inc. in November 2018. Its corporate base is located in Iselin, New Jersey.
前收盤價
US$0.5851
−US$0.0138 · -2.30%
盤前
US$0.5898
+US$0.0047 · +0.80%
10月13日 上午4:00 ET
盤中時間採用ET。市場資料可能有所延遲。
Outlook Therapeutics, Inc. is a biopharmaceutical company in the advanced stages of clinical development, focused on inventing and bringing to market monoclonal antibody treatments for various eye conditions. Its flagship drug candidate, ONS-5010, is an ophthalmic formulation of bevacizumab currently undergoing crucial Phase III clinical trials. This investigational product is being evaluated for its potential to treat wet age-related macular degeneration and other serious retinal diseases. The company has forged strategic collaboration and licensing agreements with several partners, including IPCA Laboratories Limited, Laboratorios Liomont, S.A. de C.V., BioLexis Pte. Ltd., and Zhejiang Huahai Pharmaceutical Co., Ltd. Incorporated in 2010, the firm was formerly known as Oncobiologics, Inc., changing its name to Outlook Therapeutics, Inc. in November 2018. Its corporate base is located in Iselin, New Jersey.
日內區間
目前US$0.5851
52週區間
目前US$0.5851
盤中時間採用ET。市場資料可能有所延遲。
Outlook Therapeutics, Inc. is a biopharmaceutical company in the advanced stages of clinical development, focused on inventing and bringing to market monoclonal antibody treatments for various eye conditions. Its flagship drug candidate, ONS-5010, is an ophthalmic formulation of bevacizumab currently undergoing crucial Phase III clinical trials. This investigational product is being evaluated for its potential to treat wet age-related macular degeneration and other serious retinal diseases. The company has forged strategic collaboration and licensing agreements with several partners, including IPCA Laboratories Limited, Laboratorios Liomont, S.A. de C.V., BioLexis Pte. Ltd., and Zhejiang Huahai Pharmaceutical Co., Ltd. Incorporated in 2010, the firm was formerly known as Oncobiologics, Inc., changing its name to Outlook Therapeutics, Inc. in November 2018. Its corporate base is located in Iselin, New Jersey.
日內區間
目前US$0.5851
52週區間
目前US$0.5851
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 141.35萬 USD | — | — | — | — |
| 銷貨成本 | 75.63萬 USD | — | — | 20.47萬 USD | — |
| 毛利 | 65.72萬 USD | — | — | −20.47萬 USD | — |
| 研究與開發 | 2778.06萬 USD | 4176.3萬 USD | 2645.29萬 USD | 4233.1萬 USD | 3895.8萬 USD |
| 銷售、一般及管理費用 | 3993.82萬 USD | 2994.02萬 USD | 2667.34萬 USD | 2074萬 USD | 1276.87萬 USD |
| 營業費用 | 6771.89萬 USD | 7170.32萬 USD | 5312.64萬 USD | 6286.6萬 USD | 5172.67萬 USD |
| 利息收入 | 8.97萬 USD | 90.62萬 USD | 97.15萬 USD | — | — |
| 利息支出 | 28.31萬 USD | 315.7萬 USD | 253.12萬 USD | 148.7萬 USD | 93.61萬 USD |
| 折舊和攤銷 | 11.71萬 USD | 11.39萬 USD | 4.42萬 USD | 20.47萬 USD | 26.21萬 USD |
| 營業利益 | −6706.17萬 USD | −7170.32萬 USD | −5312.64萬 USD | −6307.1萬 USD | −5172.67萬 USD |
| 淨利 | −6242.49萬 USD | −7536.67萬 USD | −5898.27萬 USD | −6605.2萬 USD | −5316.33萬 USD |
公司資料更新於 2026年10月13日。
已公布業績及可用的市場共識預估。
已公布業績及可用的市場共識預估。
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$2.80
上漲空間 378.55%報告持有此股票曝險的交易所交易基金。
AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
